Ladenburg analyst Aydin Huseynov raised the firm’s price target on Tempest Therapeutics to $14 from $8 and keeps a Buy rating on the shares. The firm said the survival data in the TPST-1120 arm looks "solid" for a Phase 1b/2 trial, and that it is "encouraged" by the early efficacy data. Ladenburg increased its probability of success for TPS-1120 to 40% from 25%, which explains the increased price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TPST:
- Tempest Soars after Positive Clinical Data for TPST-1120
- Tempest Therapeutics announces early results from Phase 1b/2 study of TPST-1120
- Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
- Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
- Tempest updates highlight differentiation across programs, says H.C. Wainwright